White WB, et al. - The antihyperglycemic efficacy and safety of the addition of the dipeptidyl dipeptidase-4 (DPP-4) inhibitor alogliptin to metformin and sulphonylurea were investigated by the experts in patients with type 2 diabetes and recent acute coronary syndrome. A marked reduction was achieved in HbA1c due to the addition of the DPP-4 inhibitor alogliptin to dual therapy with metformin plus sulfonylurea. It was found to be well tolerated. In this subgroup, findings illustrated lower mortality rates in subjects treated with aloglipti.